Exelon Corp. to Buy Pepco Holdings for $6.83B; PokerTek to be Acquired by Multimedia Games


Follow this company

Companies Mentioned

NYSE:POM / NASDAQ:MU / NASDAQ:PTEK / OTC:BB:COCP
05/01/2014 [ACCESSWIRE]

Pepco Holdings, Inc. (NYSE: POM) – For an in-depth report on Pepco Holdings, Inc. follow: www.BullTrends.com/stockquote/POM

Shares of Pepco Holdings closed up nearly 18% on Wednesday with nearly 75 million shares traded. The stock was one of the most active stocks on the NYSE and hit a new yearly high of $26.89 during intra-day trading. The big gains came after it was revealed that Exelon Corp said it would buy Pepco Holdings Inc for $6.83 billion.

Micron Technology Inc. (NASDAQ: MU) - For an in-depth report on Micron Technology Inc. follow: www.BullTrends.com/stockquote/MU

Shares of Micron Technology Inc. closed up 4.06% on nearly 29 million shares traded. The stock was one of the biggest movers on the NASDAQ and came just 50 cents shy of its yearly high. On Monday the TheStreet Ratings team hreiterated its "buy" rating for the stock.

PokerTek, Inc. (NASDAQ: PTEK) – For an in-depth report on PokerTek, Inc. follow: www.BullTrends.com/stockquote/PTEK

Shares of PokerTek closed up 33.66% on about 2 million shares traded. The stock was one of the biggest gainers on the NASDAQ. The company has entered into a definitive agreement and plan of merger with Multimedia Games, a subsidiary of Multimedia Games Holding (MGAM). Multimedia Games has agreed to acquire PokerTek at a price of $1.35 per share in cash.

Cocrystal Pharma, Inc. (OTCBB: COCP) - For an in-depth report on Cocrystal Pharma, Inc. follow: www.BullTrends.com/stockquote/COCP

Shares of COCP closed up 12.50% on about 825,000 shares traded on Wednesday. The stock was one of the biggest gainers in the OTCBB marketplace. The company updated stakeholders on its Influenza Program. The article concludes that Tamiflu, a drug widely stockpiled for use in influenza pandemics, is no more effective than paracetimol, a generic over-the-counter pain reliever and fever reducer. The company is developing drug candidates that are specifically designed to be effective against all strains of the influenza virus and to have a high barrier to resistance.

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *